【估值具吸引力+增长前景良好 瑞银上调CVS Health(CVS.US)评级至“买入”】智通财经APP获悉,瑞银将其对美国药品零售商CVS
Health(CVS.US)的股票评级由“持有”上调至“买入”,目标价由67美元上调至79美元。这一目标价较该股周一收盘价70.17美元有近13%的上涨空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.